First line treatment of metastatic renal cell carcinoma: two standards with different toxicity profile.

PubWeight™: 0.82^‹?›

🔗 View Article (PMC 3938518)

Published in Cancer Biol Ther on November 19, 2013

Authors

Roberto Iacovelli¹, Elena Verzoni², Filippo De Braud², Giuseppe Procopio²

Author Affiliations

1: Department of Medical Oncology; Fondazione IRCCS Istituto Nazionale Tumori; Milano, Italy; Department of Radiology, Oncology and Human Pathology PhD program; Sapienza University of Rome; Rome, Italy.
2: Department of Medical Oncology; Fondazione IRCCS Istituto Nazionale Tumori; Milano, Italy.

Associated clinical trials:

Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma | NCT01147822

Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma (PRINCIPAL) | NCT01649778

Articles citing this ↘

Pazopanib and HDAC inhibitors interact to kill sarcoma cells. Cancer Biol Ther (2014) 0.82

Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells. Cancer Biol Ther (2015) 0.80

Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement. J Multidiscip Healthc (2015) 0.75

Pazopanib: a Review in Advanced Renal Cell Carcinoma. Target Oncol (2017) 0.75

Articles cited by this ↗

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer (2013) 14.03

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03

Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med (2013) 10.74

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol (1999) 8.46

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16

Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer (2012) 7.68

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol (2009) 5.05

Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia. Cancer Res (2001) 1.10

Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. Br J Clin Pharmacol (2014) 1.00

Past, present and future of targeted therapy in solid tumors. Curr Cancer Drug Targets (2010) 0.95